• 1. An intermolecular C–C coupling reaction of iridium complexes?
  Kathrin Kutlescha,Rhett Kempe New J. Chem., 2010,34, 1954-1960
• 2. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 3. Acetyl group orientation modulates the electronic ground-state asymmetry of the special pair in purple bacterial reaction centers
  P. K. Wawrzyniak,M. T. P. Beerepoot,H. J. M. de Groot,F. Buda Phys. Chem. Chem. Phys., 2011,13, 10270-10279
• 4. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
• 5. An analyte-triggered artificial peroxidase system based on dimanganese complex for a versatile enzyme assay?
  Suji Lee,Min Su Han Chem. Commun., 2021,57, 9450-9453

• Solvents and Organic Chemicals Organic Compounds Benzenoids Triphenyl compounds Triphenyl compounds
• Solvents and Organic Chemicals Organic Compounds Benzenoids Triphenyl compounds

1H-Pyrazole-4-carboxylic acid, 1-(triphenylmethyl)-, ethyl ester (CAS No. 88529-68-4): A Comprehensive Overview

The compound 1H-Pyrazole-4-carboxylic acid, 1-(triphenylmethyl)-, ethyl ester, identified by its CAS number 88529-68-4, is a significant molecule in the realm of pharmaceutical chemistry and drug discovery. This heterocyclic compound features a pyrazole core, which is a privileged scaffold in medicinal chemistry due to its broad biological activity and favorable pharmacokinetic properties. The presence of an ethyl ester group and a triphenylmethyl substituent enhances its structural complexity and potential therapeutic applications.

In recent years, the exploration of novel heterocyclic compounds has gained substantial momentum in the pharmaceutical industry. Pyrazole derivatives have been extensively studied for their antimicrobial, anti-inflammatory, and anticancer properties. The specific structure of 1H-Pyrazole-4-carboxylic acid, 1-(triphenylmethyl)-, ethyl ester positions it as a promising candidate for further investigation in these areas.

The ethyl ester functionality in this compound not only contributes to its solubility and bioavailability but also serves as a versatile handle for further chemical modifications. This flexibility allows researchers to explore various derivatization strategies, enabling the development of more tailored and potent pharmacological agents. The triphenylmethyl group, on the other hand, introduces lipophilicity and steric bulk, which can influence both the compound's metabolic stability and its interaction with biological targets.

Recent studies have highlighted the importance of pyrazole derivatives in addressing unmet medical needs. For instance, a series of pyrazole-based compounds has been reported to exhibit significant inhibitory activity against various enzymes implicated in cancer progression. The mechanism of action often involves interference with key signaling pathways that drive tumor growth and metastasis. Given these findings, 1H-Pyrazole-4-carboxylic acid, 1-(triphenylmethyl)-, ethyl ester could potentially be explored as a lead compound for developing novel anticancer therapeutics.

Beyond oncology, pyrazole derivatives have shown promise in treating inflammatory diseases. The pyrazole core is known to modulate inflammatory pathways by inhibiting enzymes such as cyclooxygenase (COX) and lipoxygenase (LOX). These enzymes are critical in the production of pro-inflammatory mediators like prostaglandins and leukotrienes. By targeting these pathways, pyrazole-based compounds can exert anti-inflammatory effects without the side effects associated with traditional nonsteroidal anti-inflammatory drugs (NSAIDs).

The synthesis of 1H-Pyrazole-4-carboxylic acid, 1-(triphenylmethyl)-, ethyl ester involves multi-step organic reactions that highlight the synthetic prowess of modern medicinal chemistry. The process typically begins with the condensation of appropriate precursors to form the pyrazole ring. Subsequent functionalization steps introduce the carboxylic acid ethyl ester and the tripphenylmethyl group. Advanced synthetic techniques such as palladium-catalyzed cross-coupling reactions are often employed to ensure high yield and purity.

The pharmacological evaluation of this compound has revealed intriguing properties that warrant further investigation. In vitro studies have demonstrated its ability to inhibit certain enzymes with high selectivity. This selectivity is crucial for minimizing off-target effects and improving therapeutic efficacy. Additionally, preliminary pharmacokinetic studies suggest that the compound exhibits favorable absorption, distribution, metabolism, and excretion (ADME) profiles.

The potential applications of 1H-Pyrazole-4-carboxylic acid, 1-(triphenylmethyl)-, ethyl ester extend beyond traditional therapeutic areas. Emerging research indicates that this compound may have utility in neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Pyrazole derivatives have been shown to cross the blood-brain barrier and interact with central nervous system (CNS) targets. This property makes them attractive candidates for developing treatments that address neurological disorders.

In conclusion, 1H-Pyrazole-4-carboxylic acid, 1-(triphenylmethyl)-, ethyl ester represents a compelling molecule with significant potential in pharmaceutical development. Its unique structural features combined with promising preclinical data position it as a valuable asset in the quest for novel therapeutic agents. As research continues to uncover new biological functions of pyrazole derivatives, compounds like this one are likely to play an increasingly important role in addressing diverse medical challenges.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)